SAMPLE UB-04 CLAIM FORM

MYOBLOC®
rimabotulinumtoxinB
Injection [5,000 Units/mL]

For Product Administered in the Hospital Outpatient Setting—Effective 8/19/19



A **Fields 42 & 43:**
Enter the appropriate revenue codes and descriptions corresponding to HCPCS codes in Field 44 – eg:

0204 – Level 1 Nerve Injections
636 – Drugs requiring detailed coding
761 – Treatment Room

B **Field 44:**
Enter the appropriate HCPCS and CPT codes:

- **MYOBLOC – J0587, Botulinum Toxin Type B (per 100 Units)**
- Injection – 64616, Chemodenervation of muscles(s); cervical spinal muscle(s). Other diagnosis codes may be appropriate.

C **Field 46:**
Enter the number of billing Units. For J0587, a billing Unit is per 100 Units of MYOBLOC

Please note that not all claims processing systems allow 3 digits in this field. In these cases, Units administered that are equal to or greater than 10,000 may need to be broken down on multiple lines (eg, 99, 98, and 3 for 20,000 Units).

This billing example is for 5,000 Units.

D **Fields 56, 76-79:**
National Provider Identifier (NPI)

Field 56: Enter NPI for the Facility
Field 76: Enter NPI for the Attending Physician
Field 77: Enter NPI for the Operating Physician
Fields 78 and 79: Enter NPI for Other Provider Type

E **Fields 67-75:**
Enter the ICD-10-CM (10) diagnosis code that is appropriate for the patient. The diagnosis code for spasmodic torticollis is G24.3. Other diagnosis codes may be acceptable. Please note that Field 67 is for the principal diagnosis and Fields 68-75 are for secondary diagnosis, if necessary.

F **Field 80:**
Some payers may require that NDC numbers be entered into the electronic comment field. If required, the NDC numbers are entered with a "0" in the sixth position. See below:

- 10454-0710-10 MYOBLOC 2,500 Units/0.5 mL
- 10454-0711-10 MYOBLOC 5,000 Units/1 mL
- 10454-0712-10 MYOBLOC 10,000 Units/2 mL

The above diagnosis and procedure codes are provided as examples only. The healthcare provider is responsible for determining the appropriate codes for an individual patient.

Please see Important Safety Information and Indication (on page 2) and full Prescribing Information, including Boxed WARNING, and Medication Guide.

Abbreviations: CPT, Current Procedural Terminology; HCPCS, Healthcare Common Procedure Coding System; NDC, National Drug Code.

MYOBLOC is ready to use and requires no mixing

3 SINGLE-DOSE VIAL SIZES*

*For single-patient use.
For patients with demonstrated tolerance to botulinum toxin injection, the recommended initial dose range divided among affected muscles is 2,500 to 5,000 Units.

2,500 Units in 0.5 mL

5,000 Units in 1 mL

10,000 Units in 2 mL

For more information on MYOBLOC Reimbursement Services, call 1-888-461-2255, Option 3, or visit myoblochcp.com

IMPORTANT SAFETY INFORMATION

WARNING: DISTANT SPREAD OF TOXIN EFFECT

See full prescribing information for complete boxed WARNING.

The effects of MYOBLOC® and all botulinum toxin products may spread from the area of injection to produce symptoms consistent with botulinum toxin effects. These symptoms have been reported hours to weeks after injection. Swallowing and breathing difficulties can be life threatening and there have been reports of death. The risk of symptoms is probably greatest in children treated for spasticity but symptoms can also occur in adults, particularly in those patients who have an underlying condition that would predispose them to these symptoms.

CONTRAINDICATIONS

MYOBLOC is contraindicated in patients with:

- A known hypersensitivity to any botulinum toxin product or to any of the components in the formulation
- Infection at the proposed injection site(s)

WARNINGS AND PRECAUTIONS

- **Lack of Interchangeability Between Botulinum Toxin Products**
  The potency units of MYOBLOC are specific to the preparation and biological activity assay method utilized. Due to differences in the aspects of this assay such as the vehicle, dilution scheme, and laboratory protocols for various potency assays, potency units are not interchangeable with other preparations of botulinum toxin products and, therefore, units of biological activity of MYOBLOC cannot be compared to or converted into units of any other botulinum toxin products assessed with any other specific assay method.
- **Hypersensitivity Reactions**
  Serious hypersensitivity reactions have been reported with botulinum toxin products. Angioedema, urticaria, and rash have occurred with MYOBLOC treatment. Hypersensitivity reactions can also include anaphylaxis, serum sickness, soft tissue edema, and dyspnea. If serious and/or immediate hypersensitivity reactions occur, discontinue further injection of MYOBLOC and institute appropriate medical therapy immediately. The use of MYOBLOC in patients with a known hypersensitivity to any botulinum neurotoxin or to any of the excipients (human albumin, sucrose), could lead to a life-threatening allergic reaction.
- **Dysphagia and Breathing Difficulties**
  Treatment with MYOBLOC and other botulinum toxin products can result in swallowing or breathing difficulties. Patients with pre-existing swallowing or breathing difficulties may be more susceptible to these complications. In most cases, this is a consequence of weakening of muscles in the area of injection that are involved in breathing or swallowing. When distant effects occur, additional respiratory muscles may be involved. Deaths as a complication of severe dysphagia have been reported after treatment with botulinum toxin. Dysphagia may persist for several months and require use of a feeding tube to maintain adequate nutrition and hydration. Aspiration may result from severe dysphagia and is a particular risk when treating patients in whom swallowing or respiratory function is already compromised.
  - **Cervical Dystonia:** Treatment of cervical dystonia with botulinum toxins may weaken neck muscles that serve as accessory muscles of ventilation. This may result in a critical loss of breathing capacity in patients with respiratory disorders who may have become dependent upon these accessory muscles. There have been post-marketing reports of serious breathing difficulties, including respiratory failure, in cervical dystonia patients. Patients treated with botulinum toxin may require immediate medical attention should they develop problems with swallowing, speech or respiratory disorders. These reactions can occur within hours to weeks after injection with botulinum toxin.
  - **Pre-Existing Neuromuscular Disorders:** Individuals with peripheral motor neuropathic diseases, amyotrophic lateral sclerosis, or neuromuscular junctional disorders (e.g., myasthenia gravis or Lambert-Eaton syndrome) should be monitored particularly closely when given botulinum toxin. Patients with neuromuscular disorders may be at increased risk of clinically significant effects including severe dysphagia and respiratory compromise from typical doses of MYOBLOC.
- **Human Albumin and Transmission of Viral Diseases**
  This product contains albumin, a derivative of human blood. Based on effective donor screening and product manufacturing processes, it carries an extremely remote risk for transmission of viral diseases and variant Creutzfeldt-Jakob disease (vCJD). There is a theoretical risk for transmission of Creutzfeldt-Jakob disease (CJD), but if that risk actually exists, the risk of transmission would be considered extremely remote. No cases of transmission of viral diseases, CJD, or vCJD have ever been identified for licensed albumin or albumin contained in other licensed products.

MOST COMMON ADVERSE REACTIONS (>5% of patients and >5% more than placebo)

Cervical Dystonia: dry mouth, dysphagia, injection site pain, headache

DRUG INTERACTIONS

Aminoglycosides and Other Agents Interfering with Neuromuscular Transmission: Co-administration of MYOBLOC and aminoglycosides or other agents interfering with neuromuscular transmission (e.g., curare-like compounds) should only be performed with caution as the effect of the toxin may be potentiated. **Anticholinergic Drugs:** Use of anticholinergic drugs after administration of MYOBLOC may potentiate systemic anticholinergic effects. **Other Botulinum Neurotoxin Products**: The effect of administering different botulinum toxin products at the same time or within several months of each other is unknown. **Muscle Relaxants:** Excessive neuromuscular weakness may be exacerbated by administration of another botulinum toxin prior to the resolution of the effects of a previously administered botulinum toxin. Excessive weakness may also be exaggerated by administration of a muscle relaxant before or after administration of MYOBLOC.

INDICATION

MYOBLOC® injection is indicated for the treatment of cervical dystonia (CD) to reduce the severity of abnormal head position and neck pain associated with CD in adults.

Please refer to the full Prescribing Information and Medication Guide.

MYOBLOC®
rimabotulinumtoxinB
Injection [5,000 Units/mL]
myoblochcp.com

Supernus® Pharmaceuticals

MYOBLOC is a registered trademark of Solstice Neurosciences, LLC, a wholly-owned subsidiary of Supernus Pharmaceuticals, LLC.

© 2022 Supernus Pharmaceuticals, Inc. MYO.2022-0012.